- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04636918
Ikervis for DED Due to GVHD Post Allo-HSCT (Ikervis)
Ikervis for Prophylaxis of Dry Eye Disease Due to Graft vs Host Disease Post Allogeneic Haemtopoietic Stem Cell Transplant
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a prospective single arm interventional study.
The recruitment period will be over 12-18 months to enroll all suitable patients. The total duration of prophylaxis will be for 1 year. After completion of the period of prophylaxis, the patients will be followed up as a non-study patient as clinically indicated.
Forty subjects, undergoing allo-HSCT, will be recruited from the Singapore National Eye Centre upon referral from the Department of Hematology, Singapore General Hospital and followed up at least 5 times over a period of 12 months at the Singapore Eye Research Institute.
The images of the subject eyes will be recorded and stored electronically. These images (corneal fluorescein staining score, Lipiview, meibography, conjunctival redness, tear stability assessment) will be used in the analysis of outcome measures. The Lipiview result is in video format.
Study Type
Enrollment (Anticipated)
Phase
- Phase 4
Contacts and Locations
Study Contact
- Name: Li Lim
- Phone Number: 63224500
- Email: lim.li@singhealth.com.sg
Study Locations
-
-
-
Singapore, Singapore
- Recruiting
- Singapore Eye Research Institute
-
Contact:
- Li Lim
- Phone Number: 63224500
- Email: lim.li@singhealth.com.sg
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 13 and above
- Able to give informed consent
Exclusion Criteria:
- Presence of concurrent disease
- Unable to complete the follow up
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Single arm
Ikervis (cyclosporine 0.1%), emulsion, one drop into both eyes, once at night.
|
Prospective interventional study (single arm)
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
To assess change in basline visual acuity using LogMAR chart with prophylactic Ikervis after 3 to 5 weeks before Haematopoietic Stem Cell Transplant and 3 months, 6 months and 12 months post Haematopoietic Stem Cell Transplant.
Time Frame: Baseline, 3 months, 6 months and 1 year post-HSCT follow up
|
Visual acuity will be assessed using LogMAR chart at baseline screening and 3, 6, and 12 months post-HSCT after prophylactic Ikervis.
|
Baseline, 3 months, 6 months and 1 year post-HSCT follow up
|
To assess change in baseline intraocular pressure using non-contact tonometry with 3 months, 6 months and 12 months post Haematopoietic Stem Cell Transplant.
Time Frame: Baseline, 3 months, 6 months and 1 year post-HSCT follow up
|
Intraocular pressure (mmHg) will be assessed using non-contact tonometry at baseline screening and 3, 6, and 12 months post-HSCT after prophylactic Ikervis.
|
Baseline, 3 months, 6 months and 1 year post-HSCT follow up
|
To assess change in baseline anterior ocular health using slit lamp examination with 12 months post Haematopoietic Stem Cell Transplant.
Time Frame: Baseline screening and 1 year post-HSCT follow up
|
Slit lamp examination will be performed at baseline screening and 12 months post-HSCT after prophylactic Ikervis.
Clinical findings such as macroerosions or chemosis on cornea, or cataract will be recorded.
|
Baseline screening and 1 year post-HSCT follow up
|
To assess change in baseline posterior ocular health using fundus examination with 12 months post Haematopoietic Stem Cell Transplant.
Time Frame: Baseline screening and 1 year post-HSCT follow up
|
Fundus examination will be performed at baseline screening and 12 months post-HSCT after prophylactic Ikervis.
Clinical findings such as cup disc ratio will be graded from 0.0 to 1.0 (greater value means larger cup), hemorrhage, edema of the retina/macular will be recorded.
|
Baseline screening and 1 year post-HSCT follow up
|
To assess change of baseline dry eye symptoms with prophylactic Ikervis after 3 to 5 weeks before Haematopoietic Stem Cell Transplant and 3 months, 6 months and 12 months post Haematopoietic Stem Cell Transplant.
Time Frame: Baseline, 3 to 5 weeks from baseline (Pre-HSCT), 3 months, 6 months and 1 year post-HSCT follow up
|
Dry eye symptoms will be assessed using SPEED questionnaire (in score 0-28).
A higher score means worse dry eye symptom.
The change of dry eye symptoms will be assess from baseline before prophylactic Ikervis, 3 to 5 weeks from baseline (Pre-HSCT), and 3, 6, and 12 months post-HSCT after prophylactic Ikervis.
|
Baseline, 3 to 5 weeks from baseline (Pre-HSCT), 3 months, 6 months and 1 year post-HSCT follow up
|
To assess change of baseline non-invasive tear break up time with prophylactic Ikervis after 3 to 5 weeks before Haematopoietic Stem Cell Transplant and 3 months, 6 months and 12 months post Haematopoietic Stem Cell Transplant.
Time Frame: Baseline, 3 to 5 weeks from baseline (Pre-HSCT), 3 months, 6 months and 1 year post-HSCT follow up
|
Non-invasive tear break up time (in seconds) will be assessed using Oculus Keratography K5M.
The change of NITBUT will be assessed from baseline before prophylactic Ikervis, pre-HSCT, and 3, 6, and 12 months post-HSCT after prophylactic Ikervis.
|
Baseline, 3 to 5 weeks from baseline (Pre-HSCT), 3 months, 6 months and 1 year post-HSCT follow up
|
To assess change of baseline conjunctival redness with prophylactic Ikervis after 3 to 5 weeks before Haematopoietic Stem Cell Transplant and 3 months, 6 months and 12 months post Haematopoietic Stem Cell Transplant.
Time Frame: Baseline, 3 to 5 weeks from baseline (Pre-HSCT), 3 months, 6 months and 1 year post-HSCT follow up
|
Conjunctival Redness (in grading 0-4) will be assessed using Oculus Keratography K5M.
A higher grading means conjunctiva is more red.
The change of conjunctival redness will be assessed from baseline before prophylactic Ikervis, pre-HSCT, and 3, 6, and 12 months post-HSCT after prophylactic Ikervis.
|
Baseline, 3 to 5 weeks from baseline (Pre-HSCT), 3 months, 6 months and 1 year post-HSCT follow up
|
To assess change of baseline tear lipid thickness with prophylactic Ikervis 12 months post Haematopoietic Stem Cell Transplant.
Time Frame: Baseline and 1 year post-HSCT follow up
|
Tear lipid thickness will be measured using LipiView.
The change of tear lipid thickness will be only be assessed from baseline before prophylactic Ikervis and 12 months post-HSCT after prophylactic Ikervis.
|
Baseline and 1 year post-HSCT follow up
|
To assess change of baseline Meibomian gland status with prophylactic Ikervis 12 months post Haematopoietic Stem Cell Transplant.
Time Frame: Baseline and 1 year post-HSCT follow up
|
Meibomian gland (in grade 0-3) will be assessed using Infra-red Meibography.
We will grade the Meibomian gland disease as: 0, no loss of meibomian glands; 1, lost area was less than one third of the total area of meibomian glands; 2, lost area was between one third and two thirds of the total area of meibomian glands; 3, lost area was over two thirds of the total area of meibomian glands.
The change of meibomian gland will be assessed from baseline before prophylactic Ikervis pre-HSCT and 12 months post-HSCT after prophylactic Ikervis.
|
Baseline and 1 year post-HSCT follow up
|
To assess change of baseline tear cytokines with prophylactic Ikervis after 3 to 5 weeks after 3 to 5 weeks before Haematopoietic Stem Cell Transplant and 3 months, 6 months and 12 months post Haematopoietic Stem Cell Transplant.
Time Frame: Baseline, 3 to 5 weeks from baseline (Pre-HSCT), 3 months, 6 months and 1 year post-HSCT follow up
|
Tear cytokine will be analysed with tears extracted from Schirmers test.
The change of tear cytokines will be assess from baseline before prophylactic Ikervis, 3 to 5 weeks from baseline (Pre-HSCT), and 3, 6, and 12 months post-HSCT after prophylactic Ikervis.
|
Baseline, 3 to 5 weeks from baseline (Pre-HSCT), 3 months, 6 months and 1 year post-HSCT follow up
|
To assess change of conjunctival impression cytology 3 to 5 weeks after prophylactic Ikervis with 12 months post Haematopoietic Stem Cell Transplant.
Time Frame: 3 to 5 weeks from baseline (Pre-HSCT) and 1 year post-HSCT follow up
|
Conjunctival impression cytology will be performed using EyePrim.
The change of conjunctival impression cytology only will be assessed 3 to 5 weeks from baseline (Pre-HSCT) and 12 months post-HSCT after prophylactic Ikervis.
|
3 to 5 weeks from baseline (Pre-HSCT) and 1 year post-HSCT follow up
|
To assess change of baseline corneal fluorescein staining score with prophylactic Ikervis after 3 to 5 weeks before Haematopoietic Stem Cell Transplant and 3 months, 6 months and 12 months post Haematopoietic Stem Cell Transplant.
Time Frame: Baseline, 3 to 5 weeks from baseline (Pre-HSCT), 3 months, 6 months and 1 year post-HSCT follow up
|
Corneal fluorescein staining (in grade 0-4) will be imaged by Oculus Keratograph K5M.
A greater number indicating more intense or greater area of staining.
The change of corneal fluorescein staining will be assess from baseline before prophylactic Ikervis, 3 to 5 weeks from baseline (Pre-HSCT), and 3, 6, and 12 months post-HSCT after prophylactic Ikervis.
|
Baseline, 3 to 5 weeks from baseline (Pre-HSCT), 3 months, 6 months and 1 year post-HSCT follow up
|
To assess change of baseline Meibomian gland expressibility with prophylactic Ikervis after 3 to 5 weeks before Haematopoietic Stem Cell Transplant and 3 months, 6 months and 12 months post Haematopoietic Stem Cell Transplant.
Time Frame: Baseline, 3 to 5 weeks from baseline (Pre-HSCT), 3 months, 6 months and 1 year post-HSCT follow up
|
Meibomian gland expressibility will be assessed using Meibomian gland evaluator.
Texture of expressed secretion will be graded as liquid or viscous.
The number of expressible glands will be recorded.
The change of meibomian gland expressibility will be assess from baseline before prophylactic Ikervis, 3 to 5 weeks from baseline (Pre-HSCT), and 3, 6, and 12 months post-HSCT after prophylactic Ikervis.
|
Baseline, 3 to 5 weeks from baseline (Pre-HSCT), 3 months, 6 months and 1 year post-HSCT follow up
|
To assess Quality of Life Questionnaire at 12 months post Haematopoietic Stem Cell Transplant.
Time Frame: 1 year post-HSCT follow up
|
Quality of Life (in score 0, 1, 2, 3, 8) will be assessed using Impact of Vision Impairment Profile questionnaire at the end of the prophylactic Ikervis, 12 months post-HSCT.
The score in 0 means a lot of the time, 1 means a fair amount of the time, 2 means a little of the time, 3 means not at all, 8 means do not do this for other reasons.
|
1 year post-HSCT follow up
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Li Lim, Senior Consultant
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- R1641/38/2019
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Leukemia (Both ALL and AML)
-
Elucida OncologyTherapeutic Advances in Childhood Leukemia and Lymphoma (TACL)WithdrawnAcute Myeloid Leukemia | AML, Childhood | Relapsed Pediatric AML | Refractory Pediatric AML
-
Maximilian Stahl, MDSyndax PharmaceuticalsNot yet recruitingAcute Myeloid Leukemia | Leukemia | AML | AML, Adult | AML With Gene MutationsUnited States
-
French Innovative Leukemia OrganisationAcute Leukemia French AssociationRecruitingAML, Adult | Relapsed Adult AML | Refractory AML | FLT3-TKD Mutation | FLT3-ITDFrance
-
Goethe UniversityCompleted
-
Grupo Argentino de Tratamiento de la Leucemia AgudaCompleted
-
Daiichi Sankyo, Inc.CompletedAMLUnited States, Korea, Republic of, Taiwan, United Kingdom, France, Australia, Spain, Italy, Canada, Singapore, Germany, Netherlands, Hong Kong, Belgium, Croatia, Czechia, Hungary, Poland, Serbia
-
Gemin XCompleted
-
Eisai Inc.TerminatedPediatric Acute Myelogenous Leukemia (AML)United States, Canada, Australia
-
AvenCell Europe GmbHGCP-Service International Ltd. & Co. KGTerminatedAcute Myeloid Leukemia | Relapsed AML | Refractory AMLGermany
-
Zhejiang ACEA Pharmaceutical Co. Ltd.Recruiting
Clinical Trials on Cyclosporine Ophthalmic
-
AllerganCompletedDry Eye SyndromesUnited States
-
Center for Ophthalmic and Vision Research, LLCSun Pharmaceutical Industries LimitedCompleted
-
Hospital Universitario Dr. Jose E. GonzalezRecruitingOcular Graft-versus-host DiseaseMexico
-
Sun Pharmaceutical Industries LimitedCompleted
-
Boston SightAllerganCompletedOcular Surface DiseaseUnited States
-
Campus Bio-Medico UniversityCompletedOcular Inflammation | Ocular Surface DiseaseItaly
-
Aurinia Pharmaceuticals Inc.Completed
-
University of WaterlooSun Pharmaceutical Industries LimitedRecruiting
-
Taejoon Pharmaceutical Co., Ltd.RecruitingDry Eye SyndromeKorea, Republic of
-
Taejoon Pharmaceutical Co., Ltd.CompletedDry Eye | Dry Eye SyndromesKorea, Republic of